We performed the first proteogenomic study on a prospectively collected colon cancer cohort. Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens. Proteogenomic integration not only prioritized genomically inferred targets, such as copy-number drivers and mutation-derived neoantigens, but also yielded novel findings. Phosphoproteomics data associated Rb phosphorylation with increased proliferation and decreased apoptosis in colon cancer, which explains why this classical tumor suppressor is amplified in colon tumors and suggests a rationale for targeting Rb phosphorylation in colon cancer. Proteomics identified an association between decreased CD8 T cell infiltration and increased glycolysis in microsatellite instability-high (MSI-H) tumors, suggesting glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade. Proteogenomics presents new avenues for biological discoveries and therapeutic development. A systematic proteogenomic analysis of colon cancer reveals vulnerabilities of potential clinical value inaccessible from genomic assessment alone.

Original languageEnglish
Pages (from-to)1035-1049.e19
Issue number4
StatePublished - May 2 2019


  • RB1
  • SOX9
  • biomarkers
  • colon cancer
  • drug targets
  • glycolysis
  • immune evasion
  • proteogenomics
  • proteomics
  • tumor antigen


Dive into the research topics of 'Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities'. Together they form a unique fingerprint.

Cite this